GlassScriptPhysician profile
Lorie T Collier
NPI 1578803219
$2,938.55
in general payments reported to CMS, 2019-2025
21 companies · $820 in 2025
The $820 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $448 · 2022: $402 · 2023: $645 · 2024: $624 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $495.42 | 2021-2025 | Acthar |
| Fresenius USA Marketing, INC. | $400.41 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $285.07 | 2021-2024 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $230.81 | 2022-2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $212.49 | 2023 | Xarelto |
| Opko Pharmaceuticals, LLC | $159.84 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $149.13 | 2021-2025 | Jynarque |
| Vifor Pharma, INC. | $139.64 | 2021-2024 | Veltassa |
| Akebia Therapeutics INC | $134.53 | 2021-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $108.90 | 2022-2025 | Benlysta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $107.50 | 2023-2025 | |
| Amgen INC. | $85.34 | 2021-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $81.63 | 2023-2025 | |
| Ardelyx, INC. | $79.02 | 2023-2024 | Ibsrela |
| Novo Nordisk INC | $77.64 | 2024-2025 | Ozempic, Wegovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $39.92 | 2022-2023 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $38.02 | 2025 | Empaveli |
| Lilly USA, LLC | $34.51 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $31.70 | 2023-2024 | Lupkynis |
| Horizon Therapeutics Plc | $26.34 | 2021 | |
| Ani Pharmaceuticals, INC. | $20.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorie Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.